CYP4A22: A Potential Drug Target Or Biomarker (G284541)

Target Name: CYP4A22

NCBI ID: G284541

CYP4A22

CYP4A22: A Potential Drug Target Or Biomarker

CYP4A22, also known as CP4AM-HUMAN, is a gene that encodes for a protein known as CYP4A22. This protein is a key regulator of the CYP4A2 gene family, which is responsible for producing a wide range of metabolites that are involved in various cellular processes. One of the most interesting aspects of CYP4A22 is its potential as a drug target or biomarker.

The CYP4A22 gene was first identified in the late 1990s as a potential drug target for addiction. Studies have shown that individuals with certain genetic variations in the CYP4A2 gene are at increased risk for developing addiction. This is because individuals with these genetic variations may have reduced levels of the CYP4A22 protein, which plays a crucial role in breaking down drugs and other substances in the body.

In addition to its potential as a drug target, CYP4A22 has also been shown to be a potential biomarker for addiction. Studies have shown that individuals with certain genetic variations in the CYP4A2 gene may have reduced levels of the CYP4A22 protein, which can be used as a biomarker for addiction. This is because individuals with these genetic variations may have reduced levels of the CYP4A22 protein, which is involved in the metabolism of drugs and other substances in the body.

Another potential use for CYP4A22 as a drug target is its role in the production of other metabolites. The CYP4A22 gene has been shown to produce a wide range of metabolites, including several compounds that have been shown to have both beneficial and potentially harmful effects on the body. For example, some studies have shown that individuals with certain genetic variations in the CYP4A2 gene may have increased levels of the metabolite 2-aminobutyric acid (2-ABA), which has been shown to have both beneficial and potentially harmful effects on the body.

In conclusion, CYP4A22 is a gene that has the potential to be a drug target or biomarker. Its role as a regulator of the CYP4A2 gene family and its involvement in the production of other metabolites make it an attractive target for further research. As studies continue to uncover the potential benefits and risks of this gene, it is likely that we will see new and exciting developments in the field of drug discovery and development.

Protein Name: Cytochrome P450 Family 4 Subfamily A Member 22

Functions: Catalyzes the omega- and (omega-1)-hydroxylation of various fatty acids such as laurate and palmitate. Shows no activity towards arachidonic acid and prostaglandin A1. Lacks functional activity in the kidney and does not contribute to renal 20-hydroxyeicosatetraenoic acid (20-HETE) biosynthesis

The "CYP4A22 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP4A22 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets